World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 12 December 2020
Main ID:  NCT03676140
Date of registration: 16/09/2018
Prospective Registration: Yes
Primary sponsor: Lihir Medical Centre
Public title: Safety of Co-administration of IDA and Azithromycin for NTDs ( ComboNTDs )
Scientific title: A Cluster Randomised Trial of the Safety of Co-Administration of IDA (Ivermectin, Diethylcarbamazine and Albendazole) & Azithromycin for Integrated Treatment of Neglected Tropical Diseases
Date of first enrolment: October 1, 2018
Target sample size: 20000
Recruitment status: Completed
URL:  https://clinicaltrials.gov/show/NCT03676140
Study type:  Interventional
Study design:  Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).  
Phase:  Phase 3
Countries of recruitment
Papua New Guinea
Contacts
Name:     Lucy John, MD
Address: 
Telephone:
Email:
Affiliation:  National Department of Health of Papua New Guinea
Key inclusion & exclusion criteria

Inclusion Criteria:

- Able to give consent

Exclusion Criteria:

- Unable to give consent.

- Less than 5 years of age (not eligible for ivermectin)**

- Pregnant women (azithromycin only, not eligible for albendazole and ivermectin)

- Lactating women (Only administered azithromycin and albendazole, not eligible for
ivermectin)**

- History of allergies to the drugs being studied

- Residents who cannot swallow tablets

Note that patients that are not eligible for a specific drug will receive all other
treatments and will be followed up through the same procedure as the other participants
drug therapy to try to track any AEs attributed to specific drug combinations



Age minimum: N/A
Age maximum: N/A
Gender: All
Health Condition(s) or Problem(s) studied
Lymphatic Filariases
Scabies
Strongyloidiasis
Trachoma
Yaws
Intervention(s)
Drug: Albendazole on Day 1
Drug: Azithromycin on Day 1
Drug: Azithromycin on Day 8
Drug: Diethylcarbamazine on day 1
Drug: Ivermectin on Day 1
Primary Outcome(s)
Self Reported Adverse Event [Time Frame: 7 Days]
Secondary Outcome(s)
Secondary ID(s)
ComboNTDs - CRT
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
London School of Hygiene and Tropical Medicine
Ethics review
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history